Clinical Trial Update: Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (GO-BACK) (MK-8259-038) [Phase 4]

View source ↗

Summary

Phase 4 trial update on withdrawal of golimumab (MK-8259 / SCH900259) in participants with non-radiographic axial spondyloarthritis, completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spondyloarthritis

Drugs mentioned

• Golimumab (golimumab)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Spondyloarthritis | Phase 4 | Status: COMPLETED | Results posted: 2022-05-04